Related references
Note: Only part of the references are listed.Biosensors for circulating tumor cells (CTCs)-biomarker detection in lung and prostate cancer: Trends and prospects
Syed Harris Hussain et al.
BIOSENSORS & BIOELECTRONICS (2022)
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis
Mike Wenzel et al.
EUROPEAN UROLOGY FOCUS (2022)
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression
Sujun Chen et al.
NATURE CELL BIOLOGY (2021)
Prostate cancer hijacks the microenvironment
Phillip Thienger et al.
NATURE CELL BIOLOGY (2021)
Liquid biopsy enters the clinic - implementation issues and future challenges
Michail Ignatiadis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
Steffi Oeyen et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Maria Adamaki et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Cell-free DNA concentration and fragment size as a biomarker for prostate cancer
Emmalyn Chen et al.
SCIENTIFIC REPORTS (2021)
Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
Mauro Scaravilli et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Tian Zhang et al.
BIOMARKER RESEARCH (2021)
Measurement of the Drug Sensitivity of Single Prostate Cancer Cells
Fikri Abali et al.
CANCERS (2021)
Extracellular vesicles in prostate cancer: a narrative review
Koji Hatano et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2021)
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
H. I. Scher et al.
EUROPEAN JOURNAL OF CANCER (2021)
Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
Agus Rizal A. H. Hamid et al.
FRONTIERS IN ONCOLOGY (2021)
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Michael J. Duffy
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival
Afroditi Nanou et al.
BRITISH JOURNAL OF CANCER (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Epithelial-mesenchymal transition of circulating tumor cells in prostate cancer is promoted by survivin
Faying Yang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive for Prostate Cancer
Konrad H. Stopsack et al.
CLINICAL CANCER RESEARCH (2020)
The role of extracellular vesicles in prostate cancer with clinical applications
Yu-Ling Tai et al.
ENDOCRINE-RELATED CANCER (2020)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke et al.
EUROPEAN UROLOGY (2020)
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Manish Kohli et al.
EBIOMEDICINE (2020)
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)
Lauren C. Harshman et al.
PROSTATE (2020)
LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression
Mengfei Yao et al.
CELL DEATH & DISEASE (2020)
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression
Edmund Lau et al.
GENOME MEDICINE (2020)
Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis
Jeremy S. Frieling et al.
NEOPLASIA (2020)
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson et al.
JCO PRECISION ONCOLOGY (2020)
Deep learning of circulating tumour cells
Leonie L. Zeune et al.
NATURE MACHINE INTELLIGENCE (2020)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Kenrick Ng et al.
ONCOLOGY AND THERAPY (2020)
CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients
Taku Kato et al.
HELIYON (2020)
Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review
De-Pei Kong et al.
ASIAN JOURNAL OF ANDROLOGY (2020)
Advanced Prostate Cancer: Treatment Advances and Future Directions
Umang Swami et al.
TRENDS IN CANCER (2020)
EMT Markers in Locally-Advanced Prostate Cancer: Predicting Recurrence?
Katia A. Cheaito et al.
FRONTIERS IN ONCOLOGY (2019)
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer
Marzia Del Re et al.
BJU INTERNATIONAL (2019)
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
Sumanta K. Pal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2
Divya Bhagirath et al.
CLINICAL CANCER RESEARCH (2019)
Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone
Weiping Liang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel
Anieta M. Sieuwerts et al.
MOLECULAR ONCOLOGY (2019)
Evolution of the Liquid Biopsy in Metastatic Prostate Cancer
Jose G. Moreno et al.
UROLOGY (2019)
Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients
France-Helene Joncas et al.
PROSTATE (2019)
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
Lisanne F. van Dessel et al.
NATURE COMMUNICATIONS (2019)
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters
Su Bin Lim et al.
CANCERS (2019)
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
Anis A. Humid et al.
EUROPEAN UROLOGY (2019)
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Gillian Vandekerkhove et al.
EUROPEAN UROLOGY (2019)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Daniel Nava Rodrigues et al.
CLINICAL CANCER RESEARCH (2019)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients
Lee-Ann Tjon-Kon-Fat et al.
PROSTATE (2018)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Microfluidic technologies for circulating tumor cell isolation
Hyungseok Cho et al.
ANALYST (2018)
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
Jelena Belic et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)
Kiki C. Andree et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer
Jing Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Metastatic Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients
Afroditi Nanou et al.
Oncotarget (2018)
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto et al.
NATURE (2018)
Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay
Manjima Dhar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
Kari A. O. Tikkinen et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling
Ihsan Y. El-Sayed et al.
CANCER LETTERS (2017)
Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients
Mariantonia Logozzi et al.
CANCER LETTERS (2017)
Improving the CellSearch® system
J. F. Swennenhuis et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer
Xichun Liu et al.
JOURNAL OF UROLOGY (2016)
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
E. S. Antonarakis et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Role of androgen receptor splice variants in prostate cancer metastasis
Jin Xu et al.
ASIAN JOURNAL OF UROLOGY (2016)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Xiaoyi Huang et al.
EUROPEAN UROLOGY (2015)
Self-seeding microwell chip for the isolation and characterization of single cells
Joost F. Swennenhuis et al.
LAB ON A CHIP (2015)
Landscape of gene fusions in epithelial cancers: seq and ye shall find
Chandan Kumar-Sinha et al.
GENOME MEDICINE (2015)
Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis
S. Josson et al.
ONCOGENE (2015)
miR-34a is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Progression
Claire Corcoran et al.
PROSTATE (2014)
Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression
Yixuan Gong et al.
CANCERS (2014)
The Prostate Health Index: a new test for the detection of prostate cancer
Stacy Loeb et al.
THERAPEUTIC ADVANCES IN UROLOGY (2014)
Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis
Xavier Filella et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell–cell interaction
Minsuk Kwak et al.
Frontiers in Oncology (2013)
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
John R. Prensner et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Biology of Castration-Recurrent Prostate Cancer
Faris Azzouni et al.
UROLOGIC CLINICS OF NORTH AMERICA (2012)
Prognostic Significance of Circulating Tumor Cell Count in Patients With Metastatic Hormone-sensitive Prostate Cancer
Luis Resel Folkersma et al.
UROLOGY (2012)
Differential Expression of Matrix Metalloproteinase-2 Expression in Disseminated Tumor Cells and Micrometastasis in Bone Marrow of Patients with Nonmetastatic and Metastatic Prostate Cancer: Theoretical Considerations and Clinical Implications-An Immunocytochemical Study
Nigel P. Murray et al.
BONE MARROW RESEARCH (2012)
Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy
Tibor Szarvas et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Non-genetic cell-to-cell variability and the consequences for pharmacology
Mario Niepel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Screening for prostate cancer remains controversial
David E. Neal et al.
LANCET (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Circulating tumour cell detection on its way to routine diagnostic implementation?
Stefan Sleijfer et al.
EUROPEAN JOURNAL OF CANCER (2007)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
